Statement of Changes in Beneficial Ownership

1. Name and Address of Reporting Person
   Mulroy Michael H.
   (Last) Mulroy
   (First) Michael
   (Middle) H.
   1300 NORTH KELLOGG DRIVE, SUITE D
   ANAHEIM CA 92807

2. Issuer Name and Ticker or Trading Symbol
   QUESTCOR PHARMACEUTICALS INC [ QCOR ]

3. Date of Earliest Transaction (Month/Day/Year)
   08/14/2014

4. If Amendment, Date of Original Filed (Month/Day/Year)
   08/14/2014

5. Relationship of Reporting Person(s) to Issuer
   Director
   10% Owner
   EVP, Strat. Affairs & GC

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person

7. Nature of Indirect Beneficial Ownership (Instr. 4)

   Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/14/2014</td>
<td></td>
<td>1</td>
<td>16,072</td>
<td>D</td>
<td>D</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/14/2014</td>
<td></td>
<td>2</td>
<td>39,187</td>
<td>D</td>
<td>D</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/14/2014</td>
<td></td>
<td>3</td>
<td>18,000</td>
<td>D</td>
<td>D</td>
<td>D</td>
</tr>
</tbody>
</table>

   Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (right to buy)</td>
<td>$14.24</td>
<td>08/14/2014</td>
<td>(1)</td>
<td>51,979</td>
<td>(0)</td>
<td>Common Stock 51,979</td>
<td>(4)</td>
<td>0</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Stock Option (right to buy)</td>
<td>$35.78</td>
<td>08/14/2014</td>
<td>(1)</td>
<td>56,250</td>
<td>(7)</td>
<td>Common Stock 56,250</td>
<td>(4)</td>
<td>0</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

Explanations of Responses:

1. Pursuant to Agreement and Plan of Merger, dated April 5, 2014 (the "Merger Agreement"), by and among Mallinckrodt plc ("Mallinckrodt"), Quincy Merger Sub, Inc. and Questcor Pharmaceuticals, Inc. ("Questcor"), Mallinckrodt acquired Questcor in a merger transaction (the "Merger") which closed at 4:30 p.m. EST, on August 14, 2014 (the "Effective Time"). At the Effective Time, each share of Questcor common stock (except for certain shares defined in the Merger Agreement) converted into the right to receive, without interest, (a) $30.00 in cash and (b) 0.897 of an ordinary share of Mallinckrodt, in exchange for such share of Questcor common stock ("Merger Consideration").

2. Pursuant to terms of the Merger, at the Effective Time, each outstanding Questcor restricted share award (other than any such award subject to performance-based vesting conditions) held by Questcor executive officers converted into a number of restricted Mallinckrodt ordinary shares determined by multiplying the applicable number of restricted shares of Questcor common stock by the Equity Award Exchange Ratio.

3. Pursuant to terms of the Merger, at the Effective Time, each outstanding Questcor restricted share award held by a Questcor executive that is subject to performance-based vesting conditions was cancelled and converted into the right to receive Merger Consideration in respect of each share of Questcor common stock underlying the Questcor restricted share award.

4. Pursuant to terms of the Merger, at the Effective Time, each vested Questcor stock option held by Questcor executive officers converted into the right to receive the Merger Consideration with respect to each share of Company common stock subject to such option immediately prior to the effective time of the Merger, net of the applicable exercise price, while each unvested Questcor stock option held by Questcor executive officers converted into an option to acquire, on the same terms and conditions as were applicable to such option immediately prior to the Effective Time, a number of Mallinckrodt ordinary shares determined by multiplying the number of shares of Questcor common stock subject to such option immediately prior to the effective time of the Merger by the Equity Award Exchange Ratio.

5. (Continued from footnote 4) at an exercise price per share of Mallinckrodt ordinary shares (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (x) the exercise price per share of Questcor common stock of such Questcor stock option by (y) the Equity Award Exchange Ratio.

6. The stock option is exercisable as it vests - 25% of the shares subject to the stock option vest on the first anniversary of the grant date, while the remaining 75% of the shares vest in equal monthly installments over the following 36 months, so that all of the shares become fully vested on the fourth anniversary of the grant date of February 16, 2011.

7. The stock option is exercisable as it vests - 25% of the shares subject to the stock option vest on the first anniversary of the grant date, while the remaining 75% of the shares vest in equal monthly installments over the following 36 months, so that all of the shares become fully vested on the fourth anniversary of the grant date of February 15, 2012.

Remarks:

/s/ Michael H. Mulroy 08/18/2014

** Signature of Reporting Person  Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
* If a reporting person files a report, including all forms applicable, more than 100 persons, see Instruction 5 (b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.